No abstract

The objective: was to determine the effectiveness of the use of complex therapy in the treatment of diffuse forms of dishormonal breast dysplasia (DВD) in women of early reproductive age.Materials and methods. Under observation were 42 women with a diffuse form of BPH at the age of 25–31 years. The control group consisted of 20 healthy non-pregnant women, parity in age, social status and living conditions. The diagnosis of DВD was established on the basis of the analysis of anamnestic data, patient complaints, clinical data, X-ray and ultrasound studies carried out on the 5–7 day of the menstrual cycle.Results. In 35 (83.3%) patients, DВD developed against the background of a normal biphasic menstrual cycle, in 7 (16.7%) – with an inferior luteal phase. During an instrumental examination, 23 (54.8%) of the women were diagnosed with fibrocystic form of DВD, 15 (35.7%) had adenofibromatosis, and 4 (9.5%) had glandular cystic mastopathy.The use of Enat 400, phytochemical oncoprotectors, venotonics and sedatives provides, in the vast majority (95.2%) of patients of early reproductive age, high clinical efficacy in the treatment of DВD. According to instrumental methods of breast imaging, the regression of DВD occurred in 38 (90.5%) of young patients.Conclusions. In the treatment of DВD in patients of early reproductive age, Enat 400 in combination with other drugs, due to the antioxidant, antiproliferative, pro-apoptotic, antitumor activity of the therapy, have established themselves as effective and safe agents.

О.В. КРАВЧЕНКО д. мед. н., професор, завідувач кафедри акушерства, гінекології та перинатології Буковинського державного медичного університету Ключевые слова: климактерический синдром, миома матки, Сагенит. CORRECTION OF EARLY MENOPAUSAL DISORDERS IN WOMEN WITH ANAMNESIS OF UTERINE MYOMA О.V. Kravchenko, md, professor, head of the obstetrics, Gynecology and perinatology department, Bukovina State medical university the study of the efficacy and safety of using Sagenit in patients with uterine myoma in the anamnesis and menopausal disorders in early menopause was performed. 52 women with neurovegetative symptoms during menopause of 2 years were under the supervision. Sagenit effectively normalized hormones, quickly relieved the early perimenopausal disorders. Sagenit is not associated with sensitive receptors reproductive organs, does not lead to proliferative changes in the uterus and can be used as the drug of choice alternative to hormonal replacement therapy in women with uterine myoma in the anamnesis and climacteric disorders in early menopausal.

No abstract

The objective: is the development of rational effective methods of non-hormonal therapy of premenstrual syndrome. Materials and methods. Under observation, there were 35 women 23-38 years aged. The diagnosis of premenstrual syndrome was established on the basis of general clinical, laboratory, instrumental research methods and consultancy by psychologist and psychiatrist. Evaluation of the effectiveness of treatment was carried out according to PMS-diaries by comparing the intensity of 18 symptoms expressed in points in the dynamics of treatment. For the purpose of correcting the symptoms of premenstrual syndrome, drug therapy was proposed, which in addition to antiprostaglandins according to the traditional scheme included venentonic Normoven, magnesium preparations (Magnikum), herbal teas. Treatment was carried out during II phase in the course of 3 menstrual cycles. Results. It was found that the average total index of PMS-diaries before the start of treatment was 23.4±6.7 points, after treatment – 10.1±7.2 points. A positive effect of treatment after 1 month was recorded by 28.6% of respondents, after the ending of treatment the share of respondents was 68.6%, the average total PMS-diary index decreased by 40% or more in comparing with the initial data. According to CINM-questionnaires: after 3 months of treatment 20 (57.1%) patients showed significant improvement, 15 (42.9%) women without significant changes.. Conclusion. Studies have shown that the treatment of premenstrual syndrome should be individualized. However, the use of such medications as magnesium lactate (Magnikum), Normoven venotonics allows to increase the effectiveness of the therapy of premenstrual syndrome in 68.8% of patients. Key words: premenstrual syndrome, non-hormonal therapy.